These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 24128133)

  • 1. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
    Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
    Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
    Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
    Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
    Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
    Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
    Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
    Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probable C4d-negative accelerated acute antibody-mediated rejection due to non-HLA antibodies.
    Niikura T; Yamamoto I; Nakada Y; Kamejima S; Katsumata H; Yamakawa T; Furuya M; Mafune A; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():75-8. PubMed ID: 26031592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of C4d staining as a humoral injury marker.
    Kara M; Demir F; Ata P; Ozel L; Gumrukcu G; Unal E; Canbakan M; Gucun M; Esadoglu V; Ozdemir E; Cemel H; Titiz MI
    Transplant Proc; 2012; 44(6):1694-6. PubMed ID: 22841245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
    Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
    Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated rejection due to anti-HLA-DQ antibody after pregnancy and delivery in a female kidney transplant recipient.
    Sagasaki M; Nakada Y; Yamamoto I; Kawabe M; Yamakawa T; Katsumata H; Mafune A; Katsuma A; Kobayashi A; Koike K; Koike Y; Miki J; Yamada H; Kimura T; Tanno Y; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2018 Jul; 23 Suppl 2():81-84. PubMed ID: 29968405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute antibody-mediated rejection in paediatric renal transplant recipients.
    Kranz B; Kelsch R; Kuwertz-Bröking E; Bröcker V; Wolters HH; Konrad M
    Pediatr Nephrol; 2011 Jul; 26(7):1149-56. PubMed ID: 21461632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond Criteria and Definitions: Outcome of a Standardized Antibody-Mediated Rejection Protocol with a Diagnostic Schema Different from the Banff 2009 Criteria.
    Rendulic T; Ramon DS; Killen PD; Samaniego-Picota M; Park JM
    Clin Transpl; 2014; ():179-87. PubMed ID: 26281143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection.
    Kikić Ž; Kainz A; Kozakowski N; Oberbauer R; Regele H; Bond G; Böhmig GA
    Clin J Am Soc Nephrol; 2015 Aug; 10(8):1435-43. PubMed ID: 26071493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients.
    Yilmaz VT; Suleymanlar G; Koksoy S; Ulger BV; Ozdem S; Akbas H; Akkaya B; Kocak H
    J Invest Surg; 2016 Oct; 29(5):282-8. PubMed ID: 27002854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of late antibody-mediated rejection (C4d-mediated rejection): a single-center experience.
    Tatar E; Uslu A; Simsek C; Vardar E
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():259-62. PubMed ID: 25894167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.